Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

  • Uribe-Herranz, Mireia
  • Oliver-Caldés, Aina
  • Martínez-Micaelo, Neus
  • Español-Rego, Marta
  • Val-Casals, Maria
  • Martínez-Soler, Roberto
  • Rubio-Garcia, Elisa
  • Brunello, Valeria
  • Mihelic, Erik Z.
  • Klein-González, Nela
  • Benítez-Ribas, Daniel
  • Amigó, Núria
  • Vergara, Andrea
  • Ortiz-Maldonado, Valentín
  • Rodríguez-Lobato, Luis Gerardo
  • Delgado, Julio
  • Ortiz de Landazuri, Iñaki
  • González-Calle, Verónica
  • Cabañas, Valentín
  • Martín-Antonio, Beatriz
  • Pérez-Amill, Lorena
  • Reguera-Ortega, Juan Luis
  • Rodríguez-Otero, Paula
  • Paiva, Bruno
  • Martínez-López, Joaquín
  • Mateos, Maria Victoria
  • Pascal, Mariona
  • Urbano-Ispizúa, Álvaro
  • González-Navarro, Europa Azucena
  • Fernández de Larrea, Carlos
  • Juan, Manel
Multiple myeloma remains incurable despite advances in immunotherapies like chimeric antigen receptor (CAR) T-cell therapy. This study investigates the role of metabolites and gut microbiota in clinical outcomes in patients treated with the humanized B-cell maturation antigen (BCMA)-directed CAR-T therapy ARI0002h. Stool metabolites, particularly succinate, were associated with CAR T-cell phenotypes and persistence in patients. In CAR T-cell culture, succinate supplementation enhanced CD4+ central memory phenotype and respiratory capacity. In a murine myeloma model, a succinate-enhancing diet significantly improved CAR T-cell persistence and showed a trend toward better tumor control. Furthermore, Acidaminococcaceae, Monoglobaceae, or Akkermansiaceae, along with specific metabolites, were associated with CAR T-cell clinical outcomes. These multimodal profiles were integrated into response models, including one that identified patients likely to achieve a complete response by days 100 and 180 after infusion. These findings suggest that metabolites and gut microbiota correlate with CAR T-cell therapy responses and can be a valuable tool for risk assessment., This work has been partially supported by grants from the Instituto de Salud Carlos III (cofunded by the European Union), Spanish Ministry of Health (FIS PI18/00775, PICI18/00012 ICI19/00025, PI19/00669, PI22/00647, and complementary grant for CONCORD-023), Fondo Europeo de Desarrollo Regional “una manera de hacer Europa” 2021SGR01292 (AGAUR; Generalitat de Catalunya), “La Caixa” Foundation (CP042702/LCF/PR/GN18/50310007), RICORS-TERAV network (RD21/0017/0009 and RD21/0017/0019), Red de Terapia Celular (RD16/0011/0005), Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00369 and CB16/12/00489), Asociación Española Contra el Cáncer (LABAE21971FERN), and Fundació Bosch I Aymerich., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor, Experience from an academic phase i clinical trial

  • Castellà, Maria
  • Caballero-Baños, M.
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Suñé, Guillermo|||0000-0002-4034-4348
  • Antoñana Vildosola, Asier|||0000-0002-1404-6398
  • Boronat Barado, Anna
  • Marzal, Berta
  • Millán, Lucía
  • Martín-Antonio, B.|||0000-0003-0612-2693
  • Cid Colom, Jordi|||0000-0002-6406-0585
  • Lozano, Miquel|||0000-0003-2593-833X
  • García, E.
  • Tabera, Jaime|||0000-0002-5430-0151
  • Trias, E.
  • Perpiña, U.
  • Canals, Josep M.|||0000-0001-6829-7670
  • Baumann, Tycho|||0000-0003-4421-0088
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Campo, Elias|||0000-0001-9850-9793
  • Yagüe, Jordi|||0000-0001-8210-1929
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Rives, S.
  • Delgado, Julio|||0000-0002-5157-4376
  • Juan, Manel|||0000-0002-3064-1648
Development of semi-automated devices that can reduce the hands-on time and standardize the production of clinical-grade CAR T-cells, such as CliniMACS Prodigy from Miltenyi, is key to facilitate the development of CAR T-cell therapies, especially in academic institutions. However, the feasibility of manufacturing CAR T-cell products from heavily pre-treated patients with this system has not been demonstrated yet. Here we report and characterize the production of 28 CAR T-cell products in the context of a phase I clinical trial for CD19+ B-cell malignancies (NCT03144583). The system includes CD4-CD8 cell selection, lentiviral transduction and T-cell expansion using IL-7/IL-15. Twenty-seven out of 28 CAR T-cell products manufactured met the full list of specifications and were considered valid products. Ex vivo cell expansion lasted an average of 8.5 days and had a mean transduction rate of 30.6 ± 13.44%. All products obtained presented cytotoxic activity against CD19+ cells and were proficient in the secretion of pro-inflammatory cytokines. Expansion kinetics was slower in patient's cells compared to healthy donor's cells. However, product potency was comparable. CAR T-cell subset phenotype was highly variable among patients and largely determined by the initial product. T and T were the predominant T-cell phenotypes obtained. 38.7% of CAR T-cells obtained presented a TN or T phenotype, in average, which are the subsets capable of establishing a long-lasting T-cell memory in patients. An in-depth analysis to identify individual factors contributing to the optimal T-cell phenotype revealed that ex vivo cell expansion leads to reduced numbers of T, T, and T cells, while T cells increase, both due to cell expansion and CAR-expression. Overall, our results show for the first time that clinical-grade production of CAR T-cells for heavily pre-treated patients using CliniMACS Prodigy system is feasible, and that the obtained products meet the current quality standards of the field. Reduced ex vivo expansion may yield CAR T-cell products with increased persistence in vivo.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ligand-based CAR-T cell, Different strategies to drive T cells in future new treatments

  • Ramírez-Chacón, Alejandro
  • Betriu-Méndez, Sergi|||0000-0002-4199-1168
  • Bartoló-Ibars, Ariadna
  • González, Azucena
  • Martí, Mercè|||0000-0002-1846-0043
  • Juan, Manel|||0000-0002-3064-1648
Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues, toxicities associated with the infusion of the product, and relapses of the tumor. As a result, novel approaches are appearing aiming to solve and/or mitigate the harmful effects of CAR-T therapies. These include strategies based on the use of ligands as binding moieties or ligand-based CAR-T cells. Several proposals are currently under development, with some undergoing clinical trials to assess their potential benefits. In addition to these, therapies such as chimeric autoantibody receptor (CAAR), B-cell receptor antigen for reverse targeting (BAR), and even chimeric human leukocyte antigen (HLA) antibody receptor (CHAR) have emerged, benefiting from the advantages of antigenic ligands as antibody-binding motifs. This review focuses on the potential role that ligands can play in current and future antitumor treatments and in other types of diseases, such as autoimmune diseases or problems associated with transplantation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness

  • Bachiller, Mireia|||0000-0002-6153-4722
  • Pérez-Amill, Lorena|||0000-0003-0674-4660
  • Battram, Anthony M.|||0000-0002-9179-0639
  • Carné, Sebastian Ciro
  • Najjar, Amer M.
  • Verhoeyen, Els
  • Juan, Manel|||0000-0002-3064-1648
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Martín-Antonio, B.|||0000-0003-0612-2693
Background Chimeric antigen receptor (CAR)-T cell immunotherapy has modified the concept of treatment in hematological malignancies. In comparison with pediatric patients, where responses are maintained over many years, older patients, such as those with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM), present lower persistence of CAR-T cells that might be due to decreased fitness of T cells acquired with aging. Moreover, cord blood derived-NK cells (CB-NKs) and CAR-NK cells derived from CB-NK can be used ' off-the-shelf' as immune cells with antitumor properties for the treatment of cancer patients. However, to date, clinical studies have only demonstrated the safety of these therapies but not optimal efficacy. To confront the shortcomings of each therapy, we devised a novel approach consisting of simultaneous (CAR-)NK cell and CAR-T cell administration. In this setting, NK cells demonstrate an important immunoregulation of T cells that could be exploited to enhance the efficacy of CAR-T cells. Methods A combinatorial treatment based on either CAR-T and CAR-NK cells or CB-NK and CAR-T cells in two models of NHL and MM was performed. Antitumor efficacy was analyzed in vitro and in vivo, and parameters related to early activation, exhaustion and senescence of T cells were analyzed. Results We show that CAR-NK cells derived from CB-NK are only effective at high doses (high E:T ratio) and that their activity rapidly decreases over time in comparison with CAR-T cells. In comparison and to exploit the potential of ' off-the-shelf' CB-NK, we demonstrate that a low number of CB-NK in the CAR-T cell product promotes an early activation of CAR-T cells and their migration to MM cells leading to enhanced anti-MM efficacy. Moreover, cytokines related to CRS development were not increased, and importantly, CB-NK enhanced the fitness of both CAR pos and CAR neg T cells, promoting lower levels of exhaustion and senescence. Conclusion This study demonstrates a relevant immunoregulatory role of CB-NK collaborating with CAR-T cells to enhance their antitumor activity. A novel and different approach to consider in CAR-T cell immunotherapy studies is presented here with the goal to enhance the efficacy of the treatment.